Oppenheimer analyst Bryan Blair lowered the firm’s price target on Xylem (XYL) to $158 from $160 and keeps an Outperform rating on the shares. The firm notes shares fell 4.5% after Xylem reported solid Q1 results and reiterated confidence in 2026 guidance along with normalized positive mid-single digit organic sales and mid-teens earnings growth.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XYL: